Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
View Patent ↗The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγreceptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70 allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1.
1. A method for the production of dendritic cells, comprising adding in vitro a) an effective amount of interferon (IFN)-α or IFN-β and b) an effective amount of IFN-γ to a population of immature dendritic cells from a subject of interest; and
culturing the immature dendritic cells in vitro to produce mature dendritic cells,
wherein after subsequent stimulation of the mature dendritic cells with CD40 ligand, said mature dendritic cells produce more IL-12p70 as compared to immature dendritic cells stimulated with CD40 ligand.
2. The method of claim 1 , wherein the method comprises adding a) 0.1 pg/ml to 10 mg/ml of IFN-α or IFN-β and b) 0.1 pg/ml to 10 mg/ml of IFN-γ to the population of immature dendritic cells.
3. The method of claim 1 , wherein the method comprises adding a) 0.1 pg/ml to 10 mg/ml of IFN-α and b) 0.1 pg/ml to 10 mg/ml of IFN-γ to the population of immature dendritic cells.
4. The method of claim 1 , wherein the method further comprises adding an effective amount of lipopolysaccharide (LPS) to the immature dendritic cells in vitro.
5. The method of claim 1 , wherein the method further comprises adding an effective amount-of interleukin-1β, tumor necrosis factor (TNF)-α or both to the immature dendritic cells in vitro.
6. The method of claim 1 , wherein the immature dendritic cells are cultured in a serum-free medium.
7. The method of claim 1 , wherein the dendritic cells produce IL-12p70 at least 10-fold higher than dendritic cells from the subject of interest matured in the presence of IL-1β, TNF-α, IL-6 and prostaglandin (PG) E 2 .
8. The method of claim 1 , wherein the method comprises adding 25 ng/ml IL-1β, 50 ng/ml TNF-α, 1000 U/ml IFN-γ, 20 μg/ml poly-I:C, and 3000 U/ml IFN-α to the immature dendritic cells.
9. The method of claim 1 , comprising adding an effective amount of a) IFN-α or IFN-β b) an effective amount of IFN-γ, and c) an effective amount of poly-I:C to the immature dendritic cells in vitro.
10. The method of claim 1 , wherein the mature dendritic cells that produce IL-12 migrate in response to a CCR7 ligand.
11. The method of claim 1 , wherein the mature dendritic cells that produce IL-12 also express CD83, CD86 and CCR7 on their cell surface.
12. The method of claim 1 , further comprising adding c) an effective amount of tumor necrosis factor (TNF)-α, lipopolysaccharide (LPS), Poly I:C, or a combination thereof to the population of immature dendritic cells in vitro.
13. A method for the production of mature dendritic cells, comprising
isolating immature dendritic cells from a sample of peripheral blood obtained from a subject;
contacting the immature dendritic cells with a) an effective amount of exogenous interferon (IFN)-α or IFN-β and b) an effective amount of exogenous IFN-γ; and
contacting the immature dendritic cells with an antigen of interest that binds the Major Histocompatibility Complex (MHC),
thereby producing mature dendritic cells that present the antigen of interest, wherein after subsequent stimulation of the mature dendritic cells with CD40 ligand, said mature dendritic cells produce more IL-12p 70 as compared to immature dendritic cells stimulated with CD40 ligand.
14. The method of claim 13 , wherein the antigen is tumor-specific or specific for an infectious agent.
15. The method of claim 13 , wherein the method comprises contacting immature dendritic cells with a) 0.1 pg/ml to 10 mg/ml of IFN-α or IFN-β and b) 0.1 pg/ml to 10 mg/ml of IFN-γ.
16. The method of claim 13 , wherein the method comprises contacting the immature dendritic cells with a) 0.1 pg/ml to 10 mg/ml of IFN-α and b) 0.1 pg/ml to 10 mg/ml of IFN-γ.
17. The method of claim 13 , wherein the method comprises contacting the immature dendritic cells with 25 ng/ml IL-1β, 50 ng/ml TNF-α, 1000 U/ml IFN-γ, 20 μg/ml poly-I:C, and 3000 U/ml IFN-α.
18. A method for producing activated cytotoxic T cells, comprising,
producing mature dendritic cells; and
contacting the mature dendritic cells with CD8+ T cells,
thereby producing activated cytotoxic T cells.
19. The method of claim 18 , wherein the mature dendritic cells and the CD8+ T cells are induced in vitro.
20. The method of claim 18 , comprising contacting the immature dendritic cells with 25 ng/ml IL-1β, 50 ng/ml TNF-α, 1000 U/ml IFN-γ, 20 μg/ml poly-I:C, and 3000 U/ml IFN-α.